Opinion

Video

Choosing CAR T-cells as Third-line and Beyond Therapy for FL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
Related Content
John F. Seymour, MBBS, FRACP, PhD
October 29th 2024

BGB-16673 Shows Early Activity, Tolerability in Heavily Pretreated Waldenström Macroglobulinemia

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Courtney DiNardo, MD, MSCE, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 28th 2024

Rezatapopt Monotherapy Remains Under Study Following Discontinuation of Combination Cohort in TP53+ Solid Tumors

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute
October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

David C. Fisher, MD
October 26th 2024

Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma